|
Statera Biopharma, Inc. (STAB) Avaliação DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Statera Biopharma, Inc. (STAB) Bundle
Simplifique a avaliação Statera Biopharma, Inc. (STAB) com esta calculadora DCF personalizável! Com o Real Statera Biopharma, Inc. (STAB) Financeiras e insumos de previsão ajustável, você pode testar cenários e descobrir o valor justo Statera Biopharma, Inc. (STAB) em minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2017 |
AY2 2018 |
AY3 2019 |
AY4 2020 |
AY5 2021 |
FY1 2022 |
FY2 2023 |
FY3 2024 |
FY4 2025 |
FY5 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -5.6 | -4.8 | -2.4 | -2.6 | 38.9 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | .0 | .0 | .0 | .3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -5.6 | -4.8 | -2.4 | -2.6 | 38.7 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 8.8 | 4.1 | .0 | .6 | 2.0 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .6 | .3 | .0 | .3 | .3 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | -.4 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .2 | .1 | 2.4 | 1.1 | 4.0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | -.2 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | -71.2 | -71.2 | -71.2 | -71.2 | -71.2 | -71.2 | -71.2 | -71.2 | -71.2 | -71.2 |
| EBITAT | -5.6 | -4.8 | -2.5 | -2.8 | 66.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -6.0 | -4.6 | .5 | -4.9 | 69.1 | -3.6 | .0 | .0 | .0 | .0 |
| WACC, % | 4.03 | 4.03 | 4.03 | 4.03 | 4.03 | 4.03 | 4.03 | 4.03 | 4.03 | 4.03 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -3 | |||||||||
| Net Debt | 14 | |||||||||
| Equity Value | -18 | |||||||||
| Diluted Shares Outstanding, MM | 35 | |||||||||
| Equity Value Per Share | -0.51 |
What You Will Get
- Real STAB Financial Data: Pre-filled with Statera Biopharma’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Statera Biopharma’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive DCF Model: Features detailed unlevered and levered DCF valuation frameworks tailored for Statera Biopharma, Inc. (STAB).
- WACC Calculation Tool: Pre-configured Weighted Average Cost of Capital sheet with adjustable parameters.
- Customizable Forecast Inputs: Easily modify growth projections, capital expenditures, and discount rates specific to Statera Biopharma, Inc. (STAB).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Statera Biopharma, Inc. (STAB).
- Interactive Dashboard and Visuals: Graphical representations that summarize essential valuation metrics for straightforward analysis.
How It Works
- 1. Access the Template: Download and open the Excel file containing Statera Biopharma, Inc.'s (STAB) preloaded data.
- 2. Modify Assumptions: Adjust essential inputs such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results Instantly: The DCF model automatically calculates intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate various forecasts to assess different valuation results.
- 5. Present with Assurance: Deliver professional valuation insights to enhance your decision-making process.
Why Choose This Calculator for Statera Biopharma, Inc. (STAB)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters easily to suit your financial analysis.
- Real-Time Valuation: Observe immediate updates to Statera's valuation with input modifications.
- Preloaded Data: Comes with Statera’s actual financial metrics for swift assessments.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Investors: Accurately assess Statera Biopharma, Inc.'s (STAB) fair value prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis related to Statera Biopharma, Inc. (STAB).
- Consultants: Efficiently customize the template for valuation reports tailored to clients interested in Statera Biopharma, Inc. (STAB).
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms like Statera Biopharma, Inc. (STAB).
- Educators: Implement it as a teaching resource to illustrate valuation techniques relevant to Statera Biopharma, Inc. (STAB).
What the Template Contains
- Pre-Filled DCF Model: Statera Biopharma’s financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Statera Biopharma’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.